Comparison of Serum IL-23 and IL-17 Levels in Patients with Systemic Sclerosis and Healthy Subjects

DEMİR C., ŞAHİN A., KÜÇÜKŞAHİN O., TURGAY T. M., TÜRKÇAPAR N., ERTEN Ş., ...Daha Fazla

JOURNAL OF CLINICAL AND ANALYTICAL MEDICINE, cilt.6, sa.1, 2015 (ESCI) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 6 Sayı: 1
  • Basım Tarihi: 2015
  • Doi Numarası: 10.4328/jcam.1709
  • Dergi Adı: JOURNAL OF CLINICAL AND ANALYTICAL MEDICINE
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Anahtar Kelimeler: Interleukin-17, Interleukin-23, Systemic Sclerosis, RHEUMATOID-ARTHRITIS, DISEASE, CELLS, INTERLEUKIN-23, SCLERODERMA, EXPRESSION, PATHOGENESIS, ASSOCIATION, SUBSETS, GENE
  • Sivas Cumhuriyet Üniversitesi Adresli: Evet

Özet

Aim: Systemic Sclerosis (SSc) is a chronic autoimmune-multisystemic disease with unknown aetiology. Fibrosis, vasculopathy and immune system activation are responsible for SSc pathogenesis. Cytokines such as interleukin (IL)-17 and IL-23 may play a role in disease development, disease severity, involvement and characteristics rather than one. For this reason, we aimed to compare the serum levels of serum IL-17 and IL-23 in SSc patients and healthy controls. Material and Method: Fourty patients with SSc and fourty healthy control were included in the study. Autoantibody profiles, organ involvement of the patients were determined. Modified Rodnan skin scores (MRSS) of the patients were calculated. Serum IL-17 and IL-23 levels were measured by ELISA. Results: The patients had a mean MRSS of 13.15. Any statistically significant difference between MRSS and IL-17/IL-23 levels were not detected. (p=0.142 and p=0.668, respectively). Twenty-one (52.5%) patients had lung involvement and 16 (40%) patients had gastrointestinal involvement. Thirty-six (90%) patients were ANA positive, 21 (52.5%) patients were anti-Scl-70 positive, 6 (15%) of the patients were anti-centromere positive. The mean IL-17 levels of the patients and control group were 0.67 +/- 0.55 pg/ml and 0.52 +/- 0.10 pg/ml (Mann-Whitney U, p=0.007), respectively. The mean of IL-23 levels of healthy control group and patients were found to be 30.27 12.68 pg/ml and 29.32 +/- 10.52 pg/ml, respectively (p=0.60). There were no statistically significant relation between serum levels of IL-17/IL-23 and age, pulmonary and gastrointestinal involvement, disease severity, autoantibody profiles. The levels of IL-17 differed significantly in SSc patients and control group but not so in IL-23. Discussion: In our study we concluded that SSc is associated with IL-17, but not with IL-23. IL-17 might contribute to SSc pathogenesis, but no correlation was found between the serum levels of IL-17/IL-23 and clinical symptoms, laboratory findings or disease activity. Anti-IL-17 can be a potential therapeutic agent in SSc patients.